newsfilter
← Latest News
Business Wire·

Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights

- Enrollment continuing in trials with CYT-0851 in combination with capecitabine or gemcitabine with data expected in mid-2023 - Ended first quarter of 2023 with approximately $137.2 million in cash Cyteir